Anchiano Therapeutics Ltd.
1/3 High-Tech Village, Givat Ram, P.O. Box 39264
Jerusalem, 9139102 Israel
February 7, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: | Tonya Aldave |
J. Nolan McWilliams
Re: | Anchiano Therapeutics Ltd. |
Registration Statement on Form F-1
File No. 333-229155
Ladies and Gentlemen:
Reference is made to the Registration Statement on Form F-1 (File No. 333-229155) (the “Registration Statement”), filed by Anchiano Therapeutics Ltd. (the “Company”) with the U.S. Securities and Exchange Commission.
The Company hereby requests that the effective date for the Registration Statement be accelerated to 5:15 p.m., Eastern Time, on February 11, 2019, or as soon as practicable thereafter, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended. By separate letter the underwriters of the issuance of securities being registered have joined in this request for acceleration.
* * * * * *
If you have any questions, please do not hesitate to contact, at Mayer Brown LLP, Anna Pinedo at (212) 506-2275. We request that we be notified of the effectiveness of the Registration Statement by a telephone call to Ms. Pinedo, and that such effectiveness also be confirmed in writing.
Very truly yours, | |
/s/ Dr. Frank G. Haluska | |
Dr. Frank G. Haluska | |
Chief Executive Officer |
cc: | Anna Pinedo |
Mayer Brown LLP